# IQVIA account plan

> IQVIA provides clinical research, commercial insights and healthcare data to life-sciences firms, with FY2025 revenue of $16,310 million.

## At a glance

IQVIA sells clinical research services, commercial insights and healthcare data and technology to life-sciences companies, payers, governments and providers. It serves over 10,000 clients in over 100 countries, including nearly all of the top 100 pharmaceutical and biotech companies, and holds more than 1.2 billion non-identified patient records. FY2025 revenue was $16,310 million (up 5.9%), with net income attributable of $1,360 million and diluted EPS of $7.84; the United States provides approximately 42% of revenue. Headcount is approximately 94,000, and the company is led by Chairman and CEO Ari Bousbib.

## Business units

- **Research & Development Solutions (R&DS)** (about 55% of FY2025 revenue ($8,896 million)): Outsourced Phase I-IV clinical research, laboratory services, protocol design, biostatistics, regulatory affairs and site networks, led by W. Richard Staub, III. Since 2026 it includes Real-World Late Phase; Q2 2026 revenue rose 8.8% to $2,575 million and backlog reached $34.2 billion. Emerging biopharma is 35% of segment revenue.
- **Commercial Solutions (former TAS and CSMS)** (about 41% of Q2 2026 revenue ($1,793 million)): SaaS platforms for life-sciences commercial and clinical processes, market information, real-world data, analytics and consulting, plus contract sales and medical services. Led by Alistair Grenfell since December 2025, it grew 8.6% in Q2 2026 on patient solutions and commercial engagement services. In FY2025 TAS earned $6,626 million and CSMS $788 million.

## Strategic priorities

- **Connected Intelligence and Healthcare-grade AI**: Use proprietary data and domain expertise for AI; IQVIA has 294 agents deployed across 90 use cases and four of the top 10 pharma companies co-develop AI with it.
- **Deeper client relationships**: Be a more complete partner across R&D and commercial; IQVIA increased the number and scope of large pharma preferred partnerships.
- **Expand into the broader healthcare market**: Reach payers, providers, governments and NGOs, for example through Cedar Gate Technologies in U.S. payer analytics.
- **Acquisitions**: $1,714 million spent on acquisitions in 2025, and Charles River discovery assets acquired in Q2 2026.
- **2026 guidance**: Full-year 2026 revenue growth of 5.9% to 7.1%, adjusted EPS of $12.80 to $13 and an adjusted EBITDA margin of about 23.2%.

## Latest results

In Q2 2026 revenue rose 8.7% to $4,368 million (8.5% at constant currency) and H1 revenue reached $8,519 million (+8.6%). Commercial Solutions grew 8.6% to $1,793 million with segment profit up 10.6%, and R&DS grew 8.8% to $2,575 million with segment profit up 11.2%. R&DS net new bookings were $3,150 million, the highest since 2022, for a book-to-bill of 1.22. Net income attributable was $256 million and diluted EPS $1.53, flat as restructuring and unallocated costs rose; adjusted EPS was $3.15 (+12.1%), and full-year guidance was raised.

## Investments and deals

- **Acquisitions in 2025**: $1,714 million invested across all three segments, including Cedar Gate Technologies and Next Oncology sites.
- **Charles River discovery assets**: Acquisition completed in Q2 2026, expanding capabilities toward drug discovery.
- **AI with NVIDIA and AWS**: Agents built with NVIDIA; AWS named as preferred agentic cloud provider.
- **Share buybacks**: $950 million repurchased in H1 2026; total authorization raised to $15,725 million.
- **Restructuring**: Actions to streamline operations and reduce overcapacity, now expected to continue throughout 2026 and into 2027.

## Challenges and risks

- **AI disruption fears**: Bousbib concedes some lower-level consulting and analytics work may be displaced.
- **Contract cancellations and backlog review**: Clients can terminate on 30 to 90 days' notice, and a review of inactive trials may trim backlog by about 5%.
- **Data supply and privacy**: Dependence on third-party data suppliers, cybersecurity and AI regulation such as the EU AI Act.
- **Leverage and costs**: Total indebtedness of $16,081 million and net leverage of 3.59 times, with pass-through costs dragging margins.

## What leadership says

> "it's an opportunity, not a challenge" — Ari Bousbib, Chairman and CEO, Q4 and full year 2025 earnings call, 5 February 2026

> "We sell the final product, not the ingredients." — Ari Bousbib, Chairman and CEO, Q4 and full year 2025 earnings call, 5 February 2026

> "some lower-level consulting and analytics work may be displaced" — Ari Bousbib, Chairman and CEO, Q4 and full year 2025 earnings call, 5 February 2026


## Where a supplier can help

- **AI infrastructure and tooling**: Scaling agents across use cases under the Healthcare-grade AI priority calls for model, compute, governance and data tooling partners.
- **Clinical site and lab capacity**: Record R&DS bookings and large pharma requests for more capacity create demand for site networks, lab equipment and clinical staffing.
- **Data supply partnerships**: Dependence on third-party data suppliers makes new healthcare data sources and data-quality providers relevant.
- **Integration of acquisitions**: Integrating Cedar Gate and the Charles River discovery assets requires systems, finance and data integration support.
- **Cost and productivity programs**: Ongoing restructuring and pass-through cost pressure point to automation and procurement solutions.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report on Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/1478242/000162828026008322/iqv-20251231.htm)

Annual report · 2026-02-17

- IQVIA sells clinical research services, commercial insights and healthcare data and technology to life-sciences companies: approximately 93,000 employees, over 10,000 clients in over 100 countries, more than 1.2 billion non-identified patient records.
- FY2025 revenue $16,310 million, up 5.9% (4.8% at constant currency); net income attributable $1,360 million; diluted EPS $7.84; operating cash flow $2,654 million.
- Research & Development Solutions (CRO) is the largest segment at $8,896 million revenue (+4.3%), with backlog of $32.7 billion. Technology & Analytics Solutions earned $6,626 million (+7.6%) and Contract Sales & Medical Solutions $788 million (+9.7%).
- From 1 January 2026 there are two segments: Commercial Solutions (TAS plus CSMS) and R&DS, which takes in Real-World Late Phase.
- The addressable market is estimated at approximately $335 billion: outsourced R&D, Real-World Evidence and connected health, and tech-enabled commercial operations.
- Strategy: Connected Intelligence and Healthcare-grade AI, deeper client relationships, expansion to payers, providers and governments, and acquisitions ($1,714 million spent on acquisitions in 2025).
- Debt of $15,800 million; buyback authorization raised to $13,725 million in total; restructuring to reduce overcapacity continues through 2026.
- Main risks: contract cancellations (30 to 90 days' notice), dependence on data suppliers, privacy and AI regulation, cybersecurity, and changes in biopharma R&D budgets and outsourcing.

### [Quarterly Report on Form 10-Q for the second quarter of 2026](https://www.sec.gov/Archives/edgar/data/1478242/000162828026050211/iqv-20260630.htm)

Interim report · 2026-07-28

- Q2 2026 revenue $4,368 million, up 8.7% (8.5% at constant currency); H1 revenue $8,519 million, up 8.6%.
- First half reported on the new two-segment structure: Commercial Solutions and Research & Development Solutions, with 2025 recast.
- Commercial Solutions Q2 revenue $1,793 million (+8.6%) and segment profit $419 million (+10.6%), driven by patient solutions and commercial engagement services.
- R&DS Q2 revenue $2,575 million (+8.8%) and segment profit $526 million (+11.2%), from clinical services and lab testing volume; backlog $34.2 billion, about $9.2 billion to convert in the next twelve months.
- Q2 net income attributable $256 million and diluted EPS $1.53, flat on the prior year as restructuring ($63 million) and unallocated costs rose.
- Restructuring is now expected to continue throughout 2026 and into 2027.
- Buybacks: $950 million in H1; authorization raised to $15,725 million. Debt $16,081 million after a €950 million 4.625% note issue due 2033.
- Headcount approximately 94,000.

### [Second quarter 2026 earnings conference call (transcript)](https://allmind.ai/earnings/event/2939846)

Executive talk · Ari Bousbib, Chairman and Chief Executive Officer · 2026-07-28

- Ari Bousbib says Q2 2026 beat the high end of guidance on revenue, adjusted EBITDA and adjusted EPS ($3.15, +12.1%); organic growth accelerated to 6%.
- R&DS net new bookings were $3,150 million, the highest since 2022 (+19% year on year, book-to-bill 1.22); last-12-month bookings $11.3 billion, up 13%.
- Full-year 2026 guidance raised: revenue growth 5.9% to 7.1%, adjusted EPS $12.80 to $13, adjusted EBITDA margin flat at about 23.2%.
- R&DS revenue mix: large pharma about 50%, mid-size about 15%, emerging biopharma 35%. IQVIA says it is the largest CRO for emerging biopharma.
- Commercial Solutions organic growth is 5%. Information is about 30% of the segment, analytics and consulting about 20%, and patient solutions, technology and engagement about 50%.
- AI: 294 agents deployed across 90 use cases; four of the top 10 pharma companies co-develop AI with IQVIA. Bousbib argues AI in discovery will increase CRO demand.
- Charles River discovery assets were acquired in Q2; a review of inactive trials may trim backlog by about 5%; Investor Day on 2 December 2026.

### [Fourth quarter and full year 2025 earnings conference call (transcript)](https://allmind.ai/earnings/event/2863177)

Executive talk · Ari Bousbib, Chairman and Chief Executive Officer · 2026-02-05

- In 2025 revenue grew 6%, adjusted EPS 7% and free cash flow reached $2.1 billion; Q4 revenue was $4.364 billion (+10.3%).
- 2026 guidance: revenue $17.15 billion to $17.35 billion, adjusted EPS $12.55 to $12.85; Commercial Solutions $7.2 billion to $7.3 billion, R&DS $9.9 billion to $10 billion.
- New two-segment organisation: Commercial Solutions (TAS plus the $788 million CSMS) and R&DS (plus $674 million of real-world late-phase offerings).
- R&DS demand improving: Q4 book-to-bill 1.18, record backlog of $32.7 billion, RFP flow up double digits, win rates up.
- Bousbib rejects AI disruption fears: proprietary, regulated and dynamic data plus domain expertise make AI "an opportunity, not a challenge". IQVIA had deployed over 150 agents across over 30 use cases.
- He concedes "some lower-level consulting and analytics work may be displaced" and sees new demand for AI-enabled analytics and SaaS.
- Investments: Cedar Gate Technologies (US payer analytics), Next Oncology sites, a UK phase 1 unit, AWS as preferred agentic cloud provider, and the first full-service commercial outsourcing deal in Asia.
- CFO Ron Bruehlman's last call; Mike Fedock presented the guidance.

## Questions about IQVIA

### What does IQVIA do?

IQVIA provides clinical research services, commercial insights and healthcare data and technology to life-sciences companies and the broader healthcare market.

### What is IQVIA's revenue?

FY2025 revenue was $16,310 million, up 5.9%. Q2 2026 revenue was $4,368 million, up 8.7%.

### How many employees does IQVIA have?

Approximately 94,000 employees in over 100 countries as of mid-2026.

### Who leads IQVIA?

Ari Bousbib is Chairman and CEO; Mike Fedock is EVP and CFO.

### What is IQVIA's strategy?

IQVIA grows through Connected Intelligence and Healthcare-grade AI, deeper client relationships, expansion into payers and providers, and acquisitions.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
